Beyar Rafael
Rambam Health Care Campus and the Technion-Israel Institute of Technology, Haifa, Israel.
Rambam Maimonides Med J. 2013 Apr 30;4(2):e0009. doi: 10.5041/RMMJ.10109. Print 2013 Apr.
Four decades of innovations in the field of interventional cardiology are presented as an example for the great growth of high technology in medicine, side by side with the development of general technology and science. The field of percutaneous coronary intervention (PCI) was enabled by the development of X-ray systems, allowing us to view the pathology, and was critically dependent on courageous and imaginative physicians and scientists who developed percutaneous transluminal coronary angioplasty (PTCA), stents, and transarterial aortic valve replacement (TAVR). Today, outstanding research continues to progress, with stem cell research and IPC technologies presenting new challenges and yet taller mountains to climb. The rapid development we have witnessed was due to tight collaborations between clinical and academic institutions and industry. The combination of all these elements, with a proper mechanism to handle conflict of interest, is an essential linkage for any progress in this field. We will continue to see exponential growth of innovations and must be prepared with appropriate bodies to encourage such developments and to provide early-stage funding and support for novel ideas.
介入心脏病学领域四十年来的创新成果,被视为医学领域高科技蓬勃发展的一个典范,与通用技术和科学的发展齐头并进。X射线系统的发展使经皮冠状动脉介入治疗(PCI)领域成为可能,让我们能够观察病变情况,并且该领域严重依赖于那些勇于创新、富有想象力的医生和科学家,他们研发出了经皮腔内冠状动脉成形术(PTCA)、支架和经动脉主动脉瓣置换术(TAVR)。如今,杰出的研究仍在不断推进,干细胞研究和缺血预处理(IPC)技术带来了新的挑战,还有更高的山峰有待攀登。我们所见证的快速发展得益于临床机构、学术机构和行业之间的紧密合作。所有这些要素的结合,再加上处理利益冲突的适当机制,是该领域取得任何进展的关键纽带。我们将继续看到创新呈指数级增长,必须建立适当的机构来鼓励这种发展,并为新想法提供早期资金和支持。